 Natera, Inc. is doubling down on its growth initiatives to expand its product portfolio beyond the non-invasive prenatal testing market. The companys growth initiatives highlight strategic discrepancies between the Texas-based molecular diagnostic company and its peers, with clearer profitability paths. 